NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Forecast, Price & News

$3.28

-0.13 (-3.81%)

(As of 02:34 PM ET)

Compare

Today's Range: $3.25
▼
$3.43
50-Day Range: $3.41
▼
$5.00
52-Week Range: $3.25
▼
$6.20

Volume: 14,973 shs
Average Volume: 34,365 shs
Market Capitalization: $35.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Lantern Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 236.4% Upside
$11.00 Price Target
Short Interest: Healthy
2.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.75) to ($2.27) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

752nd out of 969 stocks

Pharmaceutical Preparations Industry

363rd out of 453 stocks

3.3

Analyst's Opinion

Consensus Rating
Lantern Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Lantern Pharma has a forecasted upside of 236.4% from its current price of $3.27.
Amount of Analyst Coverage
Lantern Pharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.09% of the float of Lantern Pharma has been sold short.
Short Interest Ratio / Days to Cover
Lantern Pharma has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Lantern Pharma has recently decreased by 3.48%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lantern Pharma does not currently pay a dividend.
Dividend Growth
Lantern Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LTRN.

2.7

News and Social Media Coverage

News Sentiment
Lantern Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lantern Pharma this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lantern Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.92% of the stock of Lantern Pharma is held by insiders.
Percentage Held by Institutions
Only 10.61% of the stock of Lantern Pharma is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lantern Pharma are expected to decrease in the coming year, from ($1.75) to ($2.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lantern Pharma has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lantern Pharma (NASDAQ:LTRN) Stock

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN Price History

30 days | 90 days | 365 days | Advanced Chart

LTRN Stock News Headlines

September 28, 2023 | marketbeat.com

8 Best Artificial Intelligence Stocks Under $10 (LTRN)

If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more.

September 29, 2023 | finance.yahoo.com

LTRN: Spotlight on LP-184 & 284

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 25, 2023 | finance.yahoo.com

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

September 18, 2023 | finance.yahoo.com

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

September 5, 2023 | msn.com

Lantern Pharma (LTRN) Price Target Increased by 18.27% to 20.91

August 31, 2023 | finance.yahoo.com

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting

August 14, 2023 | finance.yahoo.com

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 10, 2023 | finance.yahoo.com

LTRN: 2Q:23 Quarterly Update

August 10, 2023 | markets.businessinsider.com

Lantern Pharma (LTRN) Receives a Hold from H.C. Wainwright

August 9, 2023 | finance.yahoo.com

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

August 2, 2023 | finance.yahoo.com

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

July 17, 2023 | finance.yahoo.com

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

June 27, 2023 | msn.com

EF Hutton Maintains Lantern Pharma (LTRN) Buy Recommendation

June 26, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Lantern Pharma (LTRN)

June 26, 2023 | finance.yahoo.com

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

June 12, 2023 | msn.com

Lantern Pharma gets FDA clearance to begin P1 testing for LP-184

June 12, 2023 | finance.yahoo.com

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

June 8, 2023 | finance.yahoo.com

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

May 28, 2023 | hk.finance.yahoo.com

LTRN - Lantern Pharma Inc.

May 18, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Lantern Pharma (LTRN) with Neutral Recommendation

May 17, 2023 | finance.yahoo.com

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

May 10, 2023 | finance.yahoo.com

LTRN: First Harmonic Patient Dosed

May 9, 2023 | finance.yahoo.com

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

May 3, 2023 | finanznachrichten.de

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial

May 3, 2023 | finance.yahoo.com

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

See More Headlines

Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Company Calendar

Last Earnings: 8/09/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LTRN
CUSIP: N/A
CIK: 1763950
Web: www.lanternpharma.com
Phone: 972-277-1136
Fax: N/A
Employees: 22
Year Founded: 2013

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +222.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.45%
Return on Assets: -25.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.92
Quick Ratio: 16.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.16 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 10,870,000
Free Float: 10,117,000
Market Cap: $37.07 million
Optionable: Not Optionable
Beta: 0.75

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Panna Sharma PH.D. (Age 52)
Pres, CEO & Director
Comp: $633.25k

Mr. David R. Margrave (Age 62)
CFO & Sec.
Comp: $394.36k

Dr. Kishor Gopaldas Bhatia Ph.D. (Age 68)
Chief Scientific Officer & Scientific Consultant
Comp: $184.33k

Nicole Leber
Investor Relations Associate, Fin. & Admin. Coordinator

Dr. Peter L. Nara D.V.M.
M.S., Ph.D., Co-Founder & Advisor

Mr. Ernest Kitt B.S.
M.S, Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LTRN Stock - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LTRN shares.
View LTRN analyst ratings or view top-rated stocks.
What is Lantern Pharma's stock price forecast for 2023?: 2 brokers have issued 1-year price targets for Lantern Pharma's stock. Their LTRN share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price.
View analysts price targets for LTRN or view top-rated stocks among Wall Street analysts.
How have LTRN shares performed in 2023?: Lantern Pharma's stock was trading at $6.04 at the start of the year. Since then, LTRN stock has decreased by 43.5% and is now trading at $3.41.
View the best growth stocks for 2023 here.
When is Lantern Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our LTRN earnings forecast.
How were Lantern Pharma's earnings last quarter?: Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04.
What ETFs hold Lantern Pharma's stock?: ETFs with the largest weight of Lantern Pharma (NASDAQ:LTRN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Lantern Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).
When did Lantern Pharma IPO?: (LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.
What is Lantern Pharma's stock symbol?: Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN."
How do I buy shares of Lantern Pharma?: Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lantern Pharma's stock price today?: One share of LTRN stock can currently be purchased for approximately $3.41.
How much money does Lantern Pharma make?: Lantern Pharma (NASDAQ:LTRN) has a market capitalization of $37.07 million. The company earns $-14,260,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.
How can I contact Lantern Pharma?: Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The official website for the company is www.lanternpharma.com. The company can be reached via phone at 972-277-1136 or via email at info@lanternpharma.com.

This page (NASDAQ:LTRN) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial